WIE 1901
Alternative Names: WIE-1901Latest Information Update: 28 Mar 2024
At a glance
- Originator Whanin Pharmaceutical
- Class Antiepileptic drugs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Epilepsy in South Korea
- 16 Feb 2021 WIE 1901 is available for licensing as of 16 Feb 2021. https://www.whanin.com/_commonBase/content.php?co_id=outlicense_kor#
- 16 Feb 2021 Phase-I clinical trials in Epilepsy in South Korea (unspecified route) before February 2021 (Whanin Pharmaceutical pipeline, February 2021)